Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

112.52 -1.00 (-0.88%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Glaukos Corporation Common Stock

< Previous 1 2 3 4 Next >
News headline image
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces First Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2023 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Stifel Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Third Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces First Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.